Ranibizumab treatment for neovascular age-related macular degeneration: From randomized trials to clinical practice

Eye

Volumn 23, Issue 8, 2009, Pages 1633-1640

  Michalova, K ^a   Wickremasinghe, S S ^a   Tan, T H ^b   Chang, A ^b,c   Harper, C A ^a   Downie, J A ^c,d   Hunyor, A P ^e   Guymer, R H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Sydney Day Surgery   (Australia)

^c SYDNEY EYE HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e Retina Associates   (Australia)

Author keywords

Age related macular degeneration; Choroidal neovascular membrane; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; TRANSIENT ISCHEMIC ATTACK; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AUSTRALIA; CHOROIDAL NEOVASCULARIZATION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 69049121436     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.175     Document Type: Article

References (12)

1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444. (Pubitemid 44511558)
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
3. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: pier study year 1. Am J Ophthalmol 2008; 145(2): 239-248 e235.
4. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32(6): 375-413.
5. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107(8): 1593-1600. (Pubitemid 30825874)
6. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102(11): 1640-1642. (Pubitemid 15204559)
7. Lucentis FDA official information, side-effects and uses. Available athttp://www.drugs.com/pro/lucentis.html. Accessed on 12 Feb 2008.
8. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Vonthein R, Ness T et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87(4): 423-431. (Pubitemid 36399030)
9. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
10. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first year ANCHOR results. Am J Ophthalmol 2007; 111: 850-857.
11. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, for the MARINA study group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252.
12. Alexander SL, Linde-Zwirble WT, Werther W, Depperschmidt EE, Wilson LJ, Palanki R et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007; 114(12): 2174-2178. (Pubitemid 350181138)